Colleen McDonough
Pediatric Hematology-Oncology · Augusta, GANPI 1164531281
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pediatric hematology-oncology clinicians in GA, where the typical reported total is $708.
Across 22 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$129
- Y-mabs Therapeutics, Inc.$124
- Bioventus LLC$98
- Novo Nordisk$72
- USWM, LLC$72
- CSL Behring$67
- plus $185 from 6 others
Across 4 payments — averaging $111,151 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$445K
What the payments were for
- Food & beverage$72297%
- Education$253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $129 |
| Y-mabs Therapeutics, Inc. | 1 | $124 |
| Bioventus LLC | 1 | $98 |
| Novo Nordisk | 4 | $72 |
| USWM, LLC | 2 | $72 |
| CSL Behring | 3 | $67 |
| Servier Pharmaceuticals LLC | 3 | $66 |
| Global Blood Therapeutics, Inc. | 2 | $30 |
| United Therapeutics Corporation | 2 | $25 |
| Novartis | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$747 in reported general payments places this provider in the 50th percentile of 74 pediatric hematology-oncology providers in Georgia.
See all pediatric hematology-oncology providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 11 | $70,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta | $23 | $70,49811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 74 pediatric hematology-oncology providers in Georgia.
Other pediatric hematology-oncology in Augusta
- Cindy NeunertAugusta$108K
- Betty PaceAugusta$64K
- Nnenna Ukachi BadamosiAugusta$2K
- Theodore JohnsonAugusta$1K
- Afshin AmeriAugusta$942
- Eric RingAugusta$352
- Claude SportesAugusta$119
- Robert SidonioAtlanta$834K
- Shannon MeeksAtlanta$255K
- Bhavya DoshiAtlanta$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.